advertisement
Abstract #15526 Published in IGR 1-3
Latanoprost 0.005% and anterior segment uveitis
Smith SL; Pruitt CA; Sine CS; Hudgins AC; Stewart WCActa Ophthalmologica Scandinavica 1999; 77: 668-672
PURPOSE: To evaluate the association of latanoprost with anterior chamber uveitis in glaucoma patients. METHODS: The authors retrospectively reviewed 527 charts of latanoprost-treated patients with: no prior uveitis (group 1); prior uveitis but inactive at the time of the study (group 2); and active uveitis (group 3). RESULTS: In group 1, five (1.0%) of 505 patients developed uveitis after starting latanoprost. The uveitis was trace to 1+ cell in severity and delayed in onset 99.8±73.9 days. In group 2, three of 13 patients (23.1%) developed delayed uveitis (trace to 1+ cell). In group 3, none of nine patients (0%) had worsened inflammation and the intraocular pressure remained unchanged (22.8±7.8 mmHg to 22.0±7.3 mmHg) after starting latanoprost (p=0.38). CONCLUSIONS: In patients with no prior history, mild delayed uveitis with latanoprost treatment may occasionally develop. In patients with a history of uveitis, mild delayed exacerbation may potentially occur, and the intraocular pressure may not be decreased in active uveitis.
Dr. S.L. Smith, Lehmann Eye Center, Nacogdoches, TX; USA
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
